Dipeptidyl Peptidase IV Inhibitors
Links shared publicly online about this topic
Nursing Medical News about Dipeptidyl-Peptidase IV Inhibitors Diabetes Mellitus, Type 2
mdlinx.com — “Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors” View full resource at mdlinx.com
Most Recently Shared on May 21, 2010 at 8:20 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors: Postgraduate Medicine http://bit.ly/bTFRNh #Nursing
Family Med Medical News about Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors
mdlinx.com — “DPP-4 Inhibitors in Type 2 Diabetes: Importance of Selective Enzyme Inhibition and Implications for Clinical Use” View full resource at mdlinx.com
Most Recently Shared on March 2, 2010 at 10:03 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Med: DPP-4 Inhibitors in Type 2 Diabetes: Importance of Selective Enzyme Inhibition and Implications for Clinical ... http://bit.ly/bGJ555
ingentaconnect Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities a...
ingentaconnect.com — “ingentaconnect Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities a...” View full resource at ingentaconnect.com
Most Recently Shared on August 7, 2011 at 9:27 pm By:
Drugs and Devices OW OW Health
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences: (Source: Drugs) http://bit.ly/nVVqzu
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch
marketwatch.com — “Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on June 30, 2011 at 11:58 am By:
Lisa Jarvis Science Enthusiast
Astellas subsidiary Prosidion sells DPP-IV inhibitor (for type 2 diabetes) patent estate to Royalty Pharma for $609m: http://t.co/9AmdbBP
Dipeptidyl peptidase-4 inhibitors for treatment of type ... [BMJ. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 16, 2012 at 8:11 pm By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clini... http://t.co/xlDSlrNK #medicine
Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes -- Borja-Hart and Whalen 44 (6): 1046 -- The Annals of Pharmacotherapy
theannals.com — “Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes -- Borja-Hart and Whalen 44 (6): 1046 -- The Annals of Pharmacotherapy” View full resource at theannals.com
Most Recently Shared on June 6, 2010 at 3:09 am By:
Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes: Nancy L Borja-Hart, Karen L WhalenJun 1,... http://bit.ly/brPxNQ
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million - Drugs.com MedNews
drugs.com — “Jun 30, 2011 - Astellas Pharma Inc. (TOKYO 4503)( Astellas ) announced today that Prosidion s patent estate and associated royalty stream relating to the use of” View full resource at drugs.com
Most Recently Shared on June 30, 2011 at 12:06 pm By:
Drugs and Devices OW OW Health
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty... http://bit.ly/lcPT8a #drug
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes - Rosenstock - 2011 - Diabetic Medicine - Wiley Online Library
onlinelibrary.wiley.com — “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes - Rosenstock - 2011 - Diabetic Medicine - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on March 10, 2011 at 5:54 pm By:
Endocrinology Wisdom OW Health
Efficacy and safety of the dipeptidyl peptidaseâ€*4 inhibitor PFâ€*734200 added to metformin in Type 2 diabetes:... http://bit.ly/hXTsNM
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes - Rosenstock - 2011 - Diabetic Medicine - Wiley Online Library
onlinelibrary.wiley.com — “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes - Rosenstock - 2011 - Diabetic Medicine - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on March 10, 2011 at 9:30 pm By:
Efficacy and safety of the dipeptidyl peptidaseâ€*4 inhibitor PFâ€*734200 added to metformin in Type 2 diabetes:... http://bit.ly/hXTsNM
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study - Nowicki - 2011 - International Journal of Clinical Practi
onlinelibrary.wiley.com — “Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study - Nowicki - 2011 - International Journal of Clinical Practice - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on October 11, 2011 at 10:07 pm By:
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in… http://t.co/FVrFij7B viaIJCPRSS
DPP-4 Inhibitors | diabetes
diabeticlive.com — “Dipeptidyl peptidase-4 (DPP-4) Inhibitors are a group of medications that present a new approach for people who suffer from Type 2 Diabetes. The way the DDP-4 Inhibitors work is unlike any other type of glucose-lowering medications. DDP-4 Inhibitors are used for enhancing the incretion system. The incretion system is a body system that naturally lowers blood sugar. If blood sugar is high, incretion works in two ways. One way is by helping the pancreas produce more insulin. When this happens, it ” View full resource at diabeticlive.com
Most Recently Shared on June 27, 2011 at 1:51 pm By:
DPP-4 Inhibitors http://fb.me/Opno1Lto
Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man - Ahrén - Diabetes, Obesity and Metabolism - Wiley Online Library
onlinelibrary.wiley.com — “Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man - Ahrén - Diabetes, Obesity and Metabolism - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on April 22, 2011 at 11:12 pm By:
Mechanisms of Action of the DPPâ€*4 Inhibitor Vildagliptin in Man: Inhibition of dipeptidyl peptidaseâ€*4 (DPPâ€... http://bit.ly/dYFaQ9
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In Japan
medicalnewstoday.com — “Takeda Pharmaceutical Company Limited (Takeda) announced that an additional indication for NESINA® (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabet” View full resource at medicalnewstoday.com
Most Recently Shared on August 21, 2010 at 2:00 pm By:
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In J... http://mnt.to/3HHx
Sitagliptin Shows Anti-inflammatory Activity In Diabetics
medicalnewstoday.com — “The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin exerts an anti-inflammatory effect in patients with type 2 diabetes at the cellular and molecular level, according to data reported at the 71” View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2011 at 11:14 pm By:
Endocrinology Wisdom OW Health
Sitagliptin Shows Anti-inflammatory Activity In Diabetics: The dipeptidyl peptidase (DPP)-4 inhibitor sitaglipti... http://bit.ly/pxyCNx
Discovery of potent, selective, and orally bioavai... [Bioorg Med Chem. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on July 21, 2011 at 1:09 am By:
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors ta... http://1.usa.gov/qBRT5v
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
